Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. - Adasme, Melissa F.; Parisi, Daniele; Van Belle, Kristien; Salentin, Sebastian; Haupt, V. Joachim; Jennings, Gary S.; Heinrich, Jörg-Christian; Herman, Jean; Sprangers, Ben; Louat, Thierry; Moreau, Yves; Schroeder, Michael (PLoS ONE, 2020)